MCRB | Seres Therapeutics Inc
Category: Consumer goods
Quick infos Headquarters: Massachusetts, United States Trade prices Volume: Market Cap: 448.11M Prev closed: Open: 5.81 High: 5.86 Low: 5.52 52 week low: 5.41 52 week high: 25.06 Dividends: No Dividends Next ER: May 4, 2022 Before Market Opens
Earnings History Date EPS / Forecast Revenue / Forecast August 4, 2022 May 4, 2022 -0.61 / -0.52571.49M / 8.31MMarch 1, 2022 -0.52 / -0.43677.23M / 12.25MNovember 10, 2021 0.72 / -0.0544126.73M / 28.52MBeat! August 3, 2021 -0.53 / -0.375.26M / 5.86MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Jun 22, 2022 3.22 3.08 3.33
3.05
782.99K 1.90% Jun 21, 2022 3.16 2.98 3.29
2.97
1.37M 10.49% Jun 17, 2022 2.86 2.75 3.01
2.74
6.70M 4% Jun 16, 2022 2.75 2.71 2.78
2.50
2.07M -2.48% Jun 15, 2022 2.82 2.72 2.87
2.56
1.82M 4.44% Jun 14, 2022 2.70 2.81 2.85
2.59
1.17M -2.53% Jun 13, 2022 2.77 3.05 3.10
2.75
1.54M -14.51% Jun 10, 2022 3.24 3.70 3.73
3.21
1.27M -12.9% Jun 9, 2022 3.72 3.91 3.99
3.69
1.29M -3.63% Jun 8, 2022 3.86 4.15 4.29
3.85
1.88M -7.21% view more
MCRB
More profiles and info about the company News
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening finance.yahoo.com Jun 23, 2022 9:01 am
Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs finance.yahoo.com Jun 23, 2022 9:00 am
Seres Therapeutics (MCRB) Q3 Earnings and Revenues Beat Estimates finance.yahoo.com Jun 23, 2022 8:15 am
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis finance.yahoo.com Jun 23, 2022 7:33 am
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement finance.yahoo.com Jun 23, 2022 7:00 am
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates finance.yahoo.com Jun 23, 2022 7:00 am
Seres Therapeutics, Inc. to Host Earnings Call finance.yahoo.com Jun 23, 2022 6:45 am Seres Stock Tanks After Failed Ulcerative Colitis Drug Test thestreet.com Jun 23, 2022 5:26 am
Growth Investors: Industry Analysts Just Upgraded Their Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenue Forecasts By 12% finance.yahoo.com Jun 23, 2022 1:33 am
Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 12% this week, taking one-year losses to 87% finance.yahoo.com Jun 19, 2022 10:47 am MCRB,CKPT and RDBX among pre market gainers. seekingalpha.com Jun 16, 2022 8:17 pm Seres Therapeutics posts additional safety data for lead candidate seekingalpha.com Jun 7, 2022 9:29 pm CRISPR, Xencor stock falls as Piper Sandler slashes price target in biotech space seekingalpha.com May 24, 2022 12:58 am
Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman finance.yahoo.com May 23, 2022 8:00 am
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting finance.yahoo.com May 10, 2022 7:00 am
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates finance.yahoo.com May 4, 2022 8:25 am
The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider finance.yahoo.com Mar 22, 2022 12:47 pm
Seres Therapeutics to Participate in Cowen 42nd Annual Health Care Conference finance.yahoo.com Mar 3, 2022 7:00 am
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD) finance.yahoo.com Jun 23, 2022 7:00 am
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022 finance.yahoo.com Jun 23, 2022 7:00 am This company doesn't provide a dividend.
Talk about Seres Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 100 HOLD 0 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis